United States - English - NLM (National Library of Medicine)

cintex services, llc - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - ergotamine tartrate 1 mg - ergotamine tartrate and caffeine tablets are indicated as therapy to abort or prevent vascular headache; e.g., migraine, migraine variants or so-called “histaminic cephalalgia.” coadministration of ergotamine with potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (see precautions: drug interactions ), with some cases resulting in amputation. there have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine tartrate and caffeine tablets was coadministered, at least one resulting in death. because of the increased risk of ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of cyp 3a4 (e.g., ketoconazole, itraconazole) (see warnings: cyp 3a4 inhibitors ). ergotamine tartrate and caffeine tablets may cau

United States - English - NLM (National Library of Medicine)

mikart, llc - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - ergotamine tartrate 1 mg - ergotamine tartrate and caffeine tablets are indicated as therapy to abort or prevent vascular headache; e.g., migraine, migraine variants or so-called “histaminic cephalalgia.” coadministration of ergotamine with potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (see precautions: drug interactions ), with some cases resulting in amputation. there have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine tartrate and caffeine tablets was coadministered, at least one resulting in death. because of the increased risk of ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of cyp 3a4 (e.g., ketoconazole, itraconazole) (see warnings: cyp 3a4 inhibitors ). er

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - ergotamine tartrate; caffeine - oral tablet - 1mg ; 100mg

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - ergotamine tartrate 1 mg - indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia”. coadministration of ergotamine with potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (see precautions: drug interactions), with some cases resulting in amputation. there have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine tartrate and caffeine was coadministered, at least one resulting in death. because of the increased risk for ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drug and other potent inhibitors of cyp 3a4 (e.g., ketoconazole, itraconazole) (see warnings: cyp 3a4 inhibitors). ergotamine tartrate and caffeine may cause fetal harm when administered to pregnant women. ergotamine tartrate and ca

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

meda pharmaceuticals ltd - bromocriptine mesilate - oral tablet - 1mg

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - alprazolam, quantity: 1 mg - tablet - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; magnesium stearate; indigo carmine aluminium lake - indications: anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - alprazolam, quantity: 1 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; maize starch; docusate sodium; colloidal anhydrous silica; magnesium stearate; sodium benzoate; lactose monohydrate; indigo carmine aluminium lake; microcrystalline cellulose; povidone - for short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. alprazolam is not recommended as primary therapy in patients with depression. for the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks. indications as at 17 december 2001 : anxiety. short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. panic disorder. the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks. the diagnostic criteria for panic disorder in dsm-iii-r are as follows: the panic attacks (discrete periods of intense fear or discomfort), at least initially, are unexpected. later in the course of this disturbance, certain situations (e.g. driving a car or being

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - alprazolam, quantity: 1 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; maize starch; docusate sodium; colloidal anhydrous silica; magnesium stearate; sodium benzoate; lactose monohydrate; indigo carmine aluminium lake; microcrystalline cellulose; povidone - for short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. alprazolam is not recommended as primary therapy in patients with depression. for the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks. indications as at 17 december 2001 : anxiety. short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. panic disorder. the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks. the diagnostic criteria for panic disorder in dsm-iii-r are as follows: the panic attacks (discrete periods of intense fear or discomfort), at least initially, are unexpected. later in the course of this disturbance, certain situations (e.g. driving a car or being in a crowded place) may become associated with having a panic attack. these panic attacks are not triggered by situations in which the person is the focus of others' attention (as in social phobia). the diagnosis requires four such attacks within a four week period, or one or more attacks followed by at least a month of persistent fear of having another attack. the panic attacks must be characterised by at least four of the following symptoms: dyspnoea or smothering sensations; dizziness, unsteady feelings or faintness; palpitations or tachycardia; trembling or shaking; sweating; choking; nausea or abdominal distress; depersonalisation or derealisation; paraesthesiae; flushes (hot flashes) or chills; chest pain or discomfort; fear of dying; fear of going crazy or of doing something uncontrolled. note. attacks involving four or more symptoms are panic attacks; attacks involving fewer than four are limited symptom attacks. at least some of the panic attack symptoms must develop suddenly and increase in intensity within ten minutes of the beginning of the first symptom noticed in the attack. the panic attack must not be attributable to some known organic factor, e.g. amphetamine or caffeine, intoxication, hyperthyroidism. the efficacy of alprazolam in conditions where the above criteria are not met has not been established. the risk versus benefits of alprazolam use in milder disorders, which do not meet the above criteria, has not been evaluated. although current evidence supports the long-term clinical effectiveness of alprazolam in panic disorder, the continuing use of alprazolam needs to be weighed against the difficulties that can occur with dependence and discontinuation. the results of a long-term study in patients taking alprazolam (ie. beyond three months) suggest that many patients continue to benefit from alprazolam therapy and that alprazolam efficacy is maintained for up to eight months. the physician should periodically reassess the usefulness of the drug for each patient. a comparative study of alprazolam and placebo in the treatment of panic attacks in patients with panic disorder involved 543 patients over an eight week period. alprazolam was significantly more effective than placebo in reducing the total number of panic attacks (p < 0.0001); at week 4, 46.8% of alprazolam patients had achieved zero total panic attacks when compared to 27.1% of placebo patients. panic disorders are often severe, chronic illnesses that cause a high level of work and social disability, increased substance abuse and potentially increased morbidity and mortality. psychological and social factors are important in the pathogenesis of panic attacks, either acting alone or in combination with biological factors. prolonged pharmacological therapy may be used as an adjunct to psychosocial therapy in the treatment of patients with panic disorders.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amdipharm ltd. - ergotamine tartrate 1 mg; caffeine 100 mg - tablet - 1 mg - 100 mg - ergotamine tartrate 1 mg; caffeine 100 mg - ergotamine, combinations excl. psycholeptics; n02ca72 ergotamine, combinations with psycholeptics

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 1 mg - tablet, uncoated - excipient ingredients: indigo carmine; docusate sodium; sodium benzoate; lactose; sodium starch glycollate; povidone; magnesium stearate; maize starch; colloidal anhydrous silica; microcrystalline cellulose - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.